China Focus@Biotech Week Boston 2019 Successfully Drew To a Close

Share Article

The event was co-organized by MyBioGate and CUBIO Innovation Center.

News Image

With more than 400 attendees and over 260 participating organizations, China Focus@BWB - the only official event at Biotech Week Boston 2019 that is solely focused on cross-border partnership with China, has come to a fruitful finish at Boston Convention and Exhibition Center. This event was co-organized by MyBioGate and CUBIO Innovation Center. Sponsors include Simcere Innovation, Inc., Jiangsu Industry Technology Research Institute, Merits & Tree Law Offices, Gracell Biotechnologies Co., Ltd., and CELLO Health BioConsulting.

Among the attending organizations there are top Chinese pharma including Fosun pharma US, Hengrui Therapeutics, Simcere Pharmaceutical Group, Harbin Pharmaceutical Group, CSPC Pharmaceutical Group, LUYE Life Sciences, Qilu Pharma, Salubris Pharmaceuticals, and Adlai Nortye Biopharma; leading Chinese and global biotech such as Gracell Biotechnologies, Oncologie, and Zelluna Immunotherapy; well known Chinese CROs such as FMD K&L and Shanghai Medicilon Inc.; as well as reputable investment banking, high-tech focused banks, and financial advisory firm including Silicon Valley Bank, Perceptive Advisors, Torreya Partners, and Bridge Point Capital.

The forum mainly consists of four modules: the Plenary Session, company presentation (Pitch & Match), exhibition and 1-on-1 partnering, and a reception sponsored by Simcere Innovation, Inc.

The plenary session began with the welcoming opening remarks from Ms. Xinxin Li, the VP of Strategic Partnership at MyBioGate. The keynote speech “Role of China in the global life science and healthcare” was delivered by the Head of Life Science & Healthcare Relationship Banking at Silicon Valley Bank, Ms. Katherine Andersen.

The keynote was followed by four panel discussion and two featured talks. Panel 1 focused on a new cross-border partnership and new trend of globalization. Panel 2 focused on the strategies of Chinese pharma to meet the domestic and global needs for innovation. Panelist shared their own stories and understanding of “China speed”, the desire of innovation in China, the perception of innovation in the Chinese life science industry, and their diverse strategies & effort of collaborations to move forward. Panel 3 featured C-suites from several Chinese and global biotech and pharma. Focused on the rapidly growing field of oncology. Panel 4 featured a group of BD head from leading biotech and large pharma and discussed the winning recipe of licensing in a competitive landscape. After introducing each of their recent successful licensing cases, panelists actively shared their “secret sauce” of preparing for and executing a successful deal.

The two featured talks introduced the recent regulatory reforms in China and the status and outlook of CAR-T therapy in China, respectively. Dr. Haishan Xiong, senior VP Business Development at FMD K&L, gave the audience a good idea of the major changes of the regulatory landscape in China and pointed out various options for biotech & pharma outside of China to enter this massive market with great potentials. Later on, Dr. William Cao, the President and CEO of Gracell Biotechnologies, systemically introduced the progress of various subtypes of CAR-T therapies in China and its regulatory development.

One of the special session in this forum is Simcere salon and reception, including three special talks given by Drs. Harvey Lodish (Whitehead Insitute), Gordon Freeman (Dana-Farber Cancer Institute), and Alex Xu (CDE/NMPA). Afterwards, the Executive Director of Simcere Innovation Inc., Dr. Shawn Xu gave an introduction of the newly found innovation center in Boston.

This is the second time that China Focus forum came to Boston during Biotech Week Boston. “It’s highly focused themes and targeted attendee profile made it a remarkably efficient business platform for the executives of biotech, pharma, investment organizations, service providers, and academic/government both from China and the ROW.” Dr. Han Yan, Sr. Program Manager of China Focus, emphasizes “As stated in our mission and as our core value, MyBioGate will continue to connect life science and healthcare innovations between China and the rest of the world, and strive to become a leading brand in the life science and healthcare community.”

For a full list of speakers at China Focus@BWB, please visit https://events.mybiogate.com/biotechweekboston/.

The next China Focus forum will be on November 10th of 2019 in Hamburg during BIO-Europe, featuring topics including European market access, the unique innovative strength of European life science, impact of Chinese regulatory reforms on China-European collaboration, etc. Please visit https://events.mybiogate.com/europe/ to find out more details and registration information for the Hamburg event.

About China Focus

China Focus brings together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate, and foster cross-border investment and collaboration in leading biopharma innovations.

Contact Details:

Feier Chen
Marketing Manager

7707 Fannin Street
Ste. 200
Houston, TX 77054
United States

Phone: (832) 497-2220
Email: feier.chen at mybiogate.com

Source: MyBioGate Inc. (event.mybiogate.com)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Miao Guo
Visit website

Media